Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARIKA RESOURCES LIMITED Capital/Financing Update 2008

Jun 24, 2008

64420_rns_2008-06-24_5c5113ab-e91d-4ef1-9e8c-5e77a93add22.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [96 x 126] intentionally omitted <==

Announcement

Rights Issue-Cleansing Statement

25 June 2008, Sydney.

Notice under section 708AA(2)(f) of the Corporations Act 2001

On 24 June 2008, Portland Orthopaedics Limited ( Company ) (ASX: PLD) announced its intention to undertake a non-renounceable rights issue of approximately 162.9 million shares ( New Shares ) on the basis of one New Share for every one ordinary share held at 7.00pm on 3rd July 2008 ( Record Date ) at a price of 2.5 cents per New Share.

The Company gives notice under section 708AA(2)(f) of the Corporations Act 2001 ( Corporations Act ) that:

1. the Company will offer the New Shares without disclosure to investors under Part 6D.2 of the Corporations Act;

2. as at the date of this notice, the Company has complied with:

  • the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

  • section 674 of the Corporations Act; and

3. as at the date of this notice, there is no excluded information (as that term is defined in section 708AA(8) of the Corporations Act) that is required to be disclosed for the purposes of 708AA(7)(d) of the Corporations Act.

An Offer Document and an Entitlement and Acceptance Form will be mailed to eligible shareholders on or before 7 July 2008.

It is noted that key Portland shareholders have given an irrevocable commitment to subscribe for a minimum of their full entitlements under the Rights Issue, including:

  • The Chairman of Portland Mr John Lee and his associates;

  • The Chief Technology Officer, Director and Founder, Ron Sekel and associates’

  • The Chief Executive Officer of Portland, Mr John Brassil and his associates, and members of his family; and

Phone: + 61 2 9700 1533

Fax: + 61 2 9666 8544

Web: www.portland-orthopaedics.com Post: Unit 3, 44 McCauley St Matraville 2033 ABN: 92 082 839 992

==> picture [96 x 126] intentionally omitted <==

  • The Chief Financial Officer and Company Secretary of Portland, James Wynn and his associates.

If the three largest shareholders of the Company and the above listed key members of the Board and senior management subscribe for their full entitlements under the Offer, and no other Shareholder subscribes for their entitlements under the Offer, the capital structure of Portland Orthopaedics will be as follows:

Shareholder Shares % holding
GBS Venture Partners 84,037,924 30.65
EquityPartners 84,051,226 30.65
Savings Australia 40,359,498 14.72
Mr Ronald Sekel 13,795,620 5.03
RemainingShareholders 51,940,556 18.95
Total 274,184,824 100

Although the issues of New Shares to these or other major shareholders under the Rights Issue may increase their percentage holding in the Company, it is not expected to have a material effect on the control of the Company.

For your information, a copy of the Offer Document for the Rights Issue will be made available on Portland’s website http://www.pldortho.com.

For further information please contact: James A Wynn Company Secretary Portland (02) 9700 1533 End:

Phone: + 61 2 9700 1533 Fax: + 61 2 9666 8544 Web: www.portland-orthopaedics.com Post: Unit 3, 44 McCauley St Matraville 2033 ABN: 92 082 839 992